ArticleBMC cancer2026
Human papillomavirus (HPV) - driven head and neck squamous cell carcinoma (HNSCC) in a multi-ethnic developing country.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSquamous cell carcinoma is the most common type of head and neck cancer. A subset of head and neck squamous cell carcinoma (HNSCC) is caused by human papillomavirus (HPV). Data regarding HPV-driven HNSCC from low- and middle-income countries is lacking.
methodsA cross-sectional multicentre study of adult patients diagnosed with primary HNSCC between 2016 and 2020 was carried out. HPV status was determined through detection of high-risk HPV mRNA via in situ hybridization (RNAISH). Tumours were classified as being HPV-driven when there was positivity for RNAISH. p16INK4a immunohistochemistry (IHC) and HPV DNA detection and genotyping (HPVDNA) via a PCR-based method were also carried out. The prognostic utility of RNAISH, p16INK4a immunohistochemistry (IHC) alone and combined p16INK4a & HPVDNA were assessed using survival analysis.
resultsA total of 356 cases of HNSCC were assessed for HPV status. Median age was 64 years (IQR: 15), and 69.9% of patients were males. The prevalence of HPV-driven HNSCC was approximately 11.0% (95% CI: 7.9–14.7%). The vast majority of HPV-driven HNSCC were from the oropharynx (94.9%). None of the tumours originating from the oral cavity, larynx and hypopharynx were HPV-driven. Seven different genotypes were found in HPV-driven HNSCC.
conclusionsIn our cohort, HPV-driven HNSCC was primarily encountered in tumours originating from the oropharynx. HPV16 was the most frequently encountered genotype in our cohort. It is recommended that determination of HPV status be based on single testing with RNAISH or dual testing of p16INK4a IHC in conjunction with HPVDNA as an acceptable alternative in resource limited settings to improve patient stratification for treatment as well as clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.